What is the future for drug development in atherosclerosis and dyslipidaemia?

Abstract

Major companies have recently announced a reduction or termination of their work in cardiovascular disease, specifically atherosclerosis and dyslipidaemia. This editorial considers the background to these developments, relating it to the continuing development of the lipoprotein-associated phospholipase A2 inhibitor darapladib and the potential for the field in the future.

Keywords::

• atherosclerosis
• darapladib
• drug development
• dyslipidaemia
• lipoprotein-associated phospholipase A2